Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880359 | 0.76 | TP53 (0.71) | TP53MAPTPOLBSIRT2LMNA | |
| SCHEMBL15427002 | 0.75 | LMNA (0.54) | TP53MAPTLMNAMEN1KMT2A | |
| SCHEMBL880346 | 0.74 | TP53 (0.80) | TP53MAPTPOLBSIRT2LMNA | |
| SCHEMBL10280347 | 0.73 | KMT2A (0.70) | TP53MAPTPOLBLMNAMEN1 | |
| SCHEMBL880443 | 0.73 | TP53 (0.76) | TP53MAPTPOLBSIRT2LMNA | |
| SCHEMBL880433 | 0.72 | TP53 (0.69) | TP53MAPTPOLBSIRT2LMNA | |
| SCHEMBL15427062 | 0.72 | LMNA (0.62) | TP53MAPTLMNAMEN1KMT2A | |
| SCHEMBL30162895 | 0.72 | SMN1; SMN2 (0.63) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL15427005 | 0.72 | SMN1; SMN2 (0.63) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL14094474 | 0.71 | SIRT2 (0.66) | TP53MAPTPOLBSIRT2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2016-02-25 | — | — | US | disclosed |
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2016-02-25 | — | — | US | disclosed |
| US-9212209-B2 | Screening methods for spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212209-B2 | Screening methods for spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2014-07-10 | — | — | US | disclosed |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2014-07-10 | — | — | US | disclosed |
| WO-2014012050-A2 | COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, MTPN | TP53 4374/4885MAPT 1135/4885POLB 454/4885 |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MYOF, MTPN | TP53 4378/4885MAPT 800/4885POLB 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.